Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)

LUND, Sweden, March 31, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS). Top-line data is expected to be shared during the second half of 2023.

Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the role of our antibody-cleaving enzyme technology in treating rare immunologic conditions. We remain fully committed to advancing the science and delivering innovative therapies to the many patients affected by severe immunologic conditions".

The phase 2 study in GBS is an open-label, single arm, multi-center study across the UK, France, and the Netherlands evaluating the safety, tolerability, and efficacy of imlifidase in GBS patients in combination with standard of care (SoC) intravenous immunoglobulin (IVIg). Enrolled patients have received imlifidase prior to SoC. Following database lock of the single arm study, efficacy parameters from patients treated with imlifidase and SoC will be compared with an external matched cohort from the International Guillain-Barré Syndrome Outcome Study (IGOS) database at the Erasmus Medical Centre, Rotterdam, Netherlands. The outcome of the comparative efficacy analysis between the two cohorts is expected to be shared during 2024.

Professor Shahram Attarian, Head of Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille (APHM), and International Coordinating Principal Investigator in the Phase 2 study, said "In the treatment of GBS, a timely diagnosis and treatment are crucial to reducing the severity of the symptoms and minimizing long term damage. With a unique treatment approach focused on rapidly and effectively reducing IgG levels, imlifidase represents a potentially new way to treat GBS patients".

GBS is a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system affecting 1-2 in 100,000 people annually.1 It is an aggressive neurological disease which rapidly and progressively weakens the extremities. It can lead to a severe paresis of the arms and legs, with around 25% of patients requiring mechanical ventilation for weeks or months and 20% unable to walk after six months.2,3 With current standard of care, GBS is fatal in 3-7% of cases.2,4

In 2018, the U.S. Food and Drug Administration granted Orphan Drug Designation to imlifidase for the treatment of GBS.

More information about the trial is available at ClinicalTrials.gov under NCT03943589.

Contacts for more information:

Klaus Sindahl, Head of Investor Relations
M: +46 (0) 709 298 269
E: [email protected]

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: [email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.


1.  McGrogan A, et al. Neuroepidemiology. 2009; 32(2):150-63         
2.  Fletcher D, et al. Neurology. 2000 27;54(12):2311-5           
3.  Van Doom P. Presse Med. 2013;42(6 Pt 2):e193-201.           
4.  Van den Berg B, et al., Nat Rev Neurol. 2014; Aug;10(8):469-82

The following files are available for download:


Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)



SOURCE Hansa Biopharma AB

These press releases may also interest you

at 14:21
Henry's is pleased to announce that it has been acquired by Lynx Equity Limited ("Lynx") and joined its portfolio of companies. With this acquisition, Henry's is poised to grow and accelerate its delivery of world-class, innovative products and...

at 14:15
Smile Generation® and its nationwide network of trusted dental practices recently completed a two-month fundraising campaign in support of charity: water, a non-profit organization that brings clean, safe drinking water to people in need around the...

at 14:02
Northeast Delta Human Services Authority (NEDHSA) is set to host its 2023 Opioid Summit on Thursday, June 15, from 9 a.m. to 4 p.m. at the...

at 13:59
The Kinetix Group (TKG) announced the launch of TKG PACT, an insight-driven platform that helps life science companies transform how they engage with their customers. The multilayer platform leverages 25 years of insights and resources developed by...

at 13:59
PetWellClinic, one of America's fastest-growing veterinary pet-wellness franchise brands, is excited to announce a new deal to bring 5 locations to Tucson, Arizona. The brand's entrance into the Tucson market comes soon after the state's first...

at 13:59
PruittHealth, a family-owned company for more than 50 years, took over the management of Charlotte Hall Veterans Home, effective Tuesday, June 6. PruittHealth has more than two decades of proven experience and success in managing state veteran homes...

News published on and distributed by: